GEORGE B. ABERCROMBIE

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

Alaunos Therapeutics, Inc.

Filing Date Source Excerpt
2010-05-14 Mr. Abercrombie, who has been a director of the Company since its April 2010, most recently served as the President and CEO of Hoffmann-La Roche Inc. and Head of North American Pharmaceutical Operations from 2001 through December 2009.

BIOCRYST PHARMACEUTICALS INC

Filing Date Source Excerpt
2015-04-10 George B. Abercrombie was appointed to the Board in October 2011 and was elected Chairman of the Board in May 2013. The Audit Committee currently consists of Mr. Lee, as chairperson, Mr. Abercrombie and Dr. Jensen. The Compensation Committee during 2014 consisted of Mr. Erck, Mr. Abercrombie, Dr. Sanders and Dr. Jensen. The Corporate Governance and Nominating Committee consisting of Dr. Hutson, Dr. Jensen and Mr. Abercrombie. The 2014 Director Compensation table shows George B. Abercrombie received total compensation of $166,738.
2016-04-11 George B. Abercrombie was appointed to the Board in October 2011 and was elected Chairman of the Board in May 2013. ... Mr. Abercrombie's executive experience in the pharmaceutical industry and management positions with major pharmaceutical companies provide an excellent background for service on the Board.
2017-04-12 George B. Abercrombie was appointed to the Board in October 2011 and was elected Chairman of the Board in May 2013. ... Mr. Abercrombie currently serves as Chairman of the Board. ... The Company has an Audit Committee, currently consisting of Mr. Lee, as its Chairman, Mr. Abercrombie and Mr. Erck. ... The Company has a Corporate Governance and Nominating Committee consisting of Dr. Hutson, as its Chairwoman, Mr. Abercrombie, and Mr. Ingram. ... 2016 Director Compensation table shows George B. Abercrombie total compensation of $148,050.
2018-09-28 The following table provides information related to the compensation of our non-employee directors during fiscal 2017.
Name Fees Earned ($) Option Award ($) (1) (2) Non-Equity Incentive Plan Compensation All Other Compensation Total ($)
George B. Abercrombie 69,583 104,664 - - 174,247
2019-04-17 George B. Abercrombie was appointed to the Board in October 2011. ... The Company has an Audit Committee, currently consisting of Mr. Lee, as its Chairman, Mr. Abercrombie and Ms. Heggie. ... The Company has a Corporate Governance and Nominating Committee consisting of Mr. Abercrombie, as its Chairman, Dr. Hutson, and Mr. Ingram.
2020-03-31 George B. Abercrombie was appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. ... The Audit Committee also recommends to the Board the independent accountants selected to be the Company’s auditors and reviews the audit plan, financial statements and audit results. The Board has adopted an Audit Committee Charter, available on the Company’s website, that meets all applicable rules of Nasdaq and the SEC. The Audit Committee members are “independent” directors as defined by Nasdaq and the SEC and meet the heightened independence standards applicable to Audit Committee members under Nasdaq and SEC rules and meet Nasdaq’s financial literacy requirements for audit committee members. The Board has determined that each of Mr. Lee and Mr. Levin qualifies as an “audit committee financial expert,” as such term is defined by the SEC. The Audit Committee met five times during 2019. ... The Company has a Corporate Governance and Nominating Committee consisting of Mr. Abercrombie, as its Chairman, Dr. Hutson, and Mr. Ingram. The Corporate Governance and Nominating Committee selects persons for election or re-election as directors and provides oversight of the corporate governance affairs and policies of the Board of Directors and the Company. The Board has adopted a Corporate Governance and Nominating Committee Charter, available on the Company’s website, that meets all applicable rules of Nasdaq and the SEC. The Corporate Governance and Nominating Committee members are “independent” directors as defined by Nasdaq. The Corporate Governance and Nominating Committee met 11 times during 2019. ... 2019 DIRECTOR COMPENSATION ... The following table provides information related to the compensation of our non-employee directors during fiscal 2019. ... George B. Abercrombie 70,625 59,088 – – 129,713 ... The Audit Committee currently consists of Mr. Lee, as Chairman, Mr. Abercrombie, Ms. Heggie, and Mr. Levin.
2021-04-13 George B. Abercrombie was initially appointed to the Board in October 2011. ... The Company has an Audit Committee, currently consisting of Mr. Lee, as its Chairman, Mr. Abercrombie, and Mr. Levin. ... The Company has a Corporate Governance and Nominating Committee consisting of Mr. Abercrombie, as its Chairman, Dr. Hutson, and Mr. Ingram. ... 2020 DIRECTOR COMPENSATION ... George B. Abercrombie 217,185
2023-04-27 George B. Abercrombie was initially appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry... The Company’s Audit Committee currently consists of Mr. Lee, as its Chair, Mr. Abercrombie, Ms. Heggie (since February 2023), Mr. Levin, and Mr. Milano... The Company’s Corporate Governance and Nominating Committee currently consists of Ms. Heggie, as its Chair (since February 2023), Mr. Abercrombie, Dr. Hutson, and Dr. McKee... 2022 Director Compensation: George B. Abercrombie total compensation $437,348.

Data sourced from SEC filings. Last updated: 2026-02-03